Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1988;66(2):177–196.

Development of recommendations for the protection of short-stay travellers to malaria endemic areas: Memorandum from two WHO Meetings*

PMCID: PMC2491041  PMID: 3293826

Abstract

In the past, since malaria chemoprophylaxis was assumed to be of benefit and with no serious complications, it was recommended to all travellers who were at risk of acquiring the disease. The current epidemiological situation of malaria is marked by the increasing spread of Plasmodium falciparum resistance to chloroquine and by problems due to the toxicity of other drugs. Recommendations for malaria prophylaxis should therefore be based on an epidemiological approach which takes into account the risk of acquiring the infection, the toxicity and effectiveness of the available antimalarial drugs, the traveller's perception of these risks, and the human factors that influence the use of all possible protective measures against malaria.

This Memorandum describes the epidemiological approach and the data bases required for the development of recommendations on prophylaxis for short-stay visitors in malaria endemic areas, and gives guidelines on the protective measures and drugs that may be used in defined situations.

Full text

PDF
177

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Björkman A., Brohult J., Sirleaf V., Willcox M., Bengtsson E. Plasmodium falciparum resistance to pyrimethamine and chlorproguanil -- host or parasite dependent? Ann Trop Med Parasitol. 1980 Apr;74(2):245–248. doi: 10.1080/00034983.1980.11687336. [DOI] [PubMed] [Google Scholar]
  2. Danis M., Diquet B., Turk P., Brousse G., Bretagne S., Dufourg P. Pharmacocinétique de la chloroquine à doses prophylactiques chez 10 volontaires sains. Résultats préliminaires. Bull Soc Pathol Exot Filiales. 1985;78(5 Pt 2):953–958. [PubMed] [Google Scholar]
  3. Frost P., Weinstein G. D., Gomez E. C. Phototoxic potential of minocycline and doxycycline. Arch Dermatol. 1972 May;105(5):681–683. [PubMed] [Google Scholar]
  4. Hatton C. S., Peto T. E., Bunch C., Pasvol G., Russell S. J., Singer C. R., Edwards G., Winstanley P. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet. 1986 Feb 22;1(8478):411–414. doi: 10.1016/s0140-6736(86)92371-8. [DOI] [PubMed] [Google Scholar]
  5. Krüger-Thiemer E., Berlin H., Brante G., Bünger P., Dettli L., Spring P., Wempe E. Dosage regimen calculation of chemotherapeutic agents. V. 2-Sulfanilamido-3-methoxy-pyrazine (Sulfalene). Chemotherapy. 1969;14(5):273–302. doi: 10.1159/000220637. [DOI] [PubMed] [Google Scholar]
  6. Lobel H. O., Campbell C. C., Pappaioanou M., Huong A. Y. Use of prophylaxis for malaria by American travelers to Africa and Haiti. JAMA. 1987 May 15;257(19):2626–2627. [PubMed] [Google Scholar]
  7. Lobel H. O., Campbell C. C., Roberts J. M. Fatal malaria in US civilians. Lancet. 1985 Apr 13;1(8433):873–873. doi: 10.1016/s0140-6736(85)92232-9. [DOI] [PubMed] [Google Scholar]
  8. Miller K. D., Lobel H. O., Satriale R. F., Kuritsky J. N., Stern R., Campbell C. C. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg. 1986 May;35(3):451–458. doi: 10.4269/ajtmh.1986.35.451. [DOI] [PubMed] [Google Scholar]
  9. Neftel K. A., Woodtly W., Schmid M., Frick P. G., Fehr J. Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 1986 Mar 15;292(6522):721–723. doi: 10.1136/bmj.292.6522.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Pang L. W., Limsomwong N., Boudreau E. F., Singharaj P. Doxycycline prophylaxis for falciparum malaria. Lancet. 1987 May 23;1(8543):1161–1164. doi: 10.1016/s0140-6736(87)92141-6. [DOI] [PubMed] [Google Scholar]
  11. Patchen L. C., Mount D. L., Schwartz I. K., Churchill F. C. Analysis of filter-paper-absorbed, finger-stick blood samples for chloroquine and its major metabolite using high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1983 Nov 11;278(1):81–89. doi: 10.1016/s0378-4347(00)84758-1. [DOI] [PubMed] [Google Scholar]
  12. Peto T. E., Gilks C. F. Strategies for the prevention of malaria in travellers: comparison of drug regimens by means of risk-benefit analysis. Lancet. 1986 May 31;1(8492):1256–1261. doi: 10.1016/s0140-6736(86)91395-4. [DOI] [PubMed] [Google Scholar]
  13. Phillips-Howard P. A., Blaze M., Hurn M., Bradley D. J. Malaria prophylaxis: survey of the response of British travellers to prophylactic advice. Br Med J (Clin Res Ed) 1986 Oct 11;293(6552):932–934. doi: 10.1136/bmj.293.6552.932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Phillips-Howard P. A., Bradley D. J., Blaze M., Hurn M. Malaria in Britain: 1977-86. Br Med J (Clin Res Ed) 1988 Jan 23;296(6617):245–248. doi: 10.1136/bmj.296.6617.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rhodes E. G., Ball J., Franklin I. M. Amodiaquine induced agranulocytosis: inhibition of colony growth in bone marrow by antimalarial agents. Br Med J (Clin Res Ed) 1986 Mar 15;292(6522):717–718. doi: 10.1136/bmj.292.6522.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rombo L., Stenbeck J., Lobel H. O., Campbell C. C., Papaioanou M., Miller K. D. Does chloroquine contribute to the risk of serious adverse reactions to fansidar? Lancet. 1985 Dec 7;2(8467):1298–1299. doi: 10.1016/s0140-6736(85)91574-0. [DOI] [PubMed] [Google Scholar]
  17. Schwartz D. E., Weber W., Richard-Lenoble D., Gentilini M. Kinetic studies of mefloquine and of one of its metabolites, Ro 21-5104, in the dog and in man. Acta Trop. 1980 Sep;37(3):238–242. [PubMed] [Google Scholar]
  18. Serembe M. A multi-centre trial of alpha-6-desoxy-5-oxytetracycline (doxycycline). Chemotherapy. 1975;21 (Suppl 1):121–129. doi: 10.1159/000221898. [DOI] [PubMed] [Google Scholar]
  19. Steffen R., Somaini B. Severe cutaneous adverse reactions to sulfadoxine-pyrimethamine in Switzerland. Lancet. 1986 Mar 15;1(8481):610–610. doi: 10.1016/s0140-6736(86)92825-4. [DOI] [PubMed] [Google Scholar]
  20. Venning G. R. Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems. Br Med J (Clin Res Ed) 1983 Feb 5;286(6363):458–460. doi: 10.1136/bmj.286.6363.458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Venning G. R. Identification of adverse reactions to new drugs. IV--Verification of suspected adverse reactions. Br Med J (Clin Res Ed) 1983 Feb 12;286(6364):544–547. doi: 10.1136/bmj.286.6364.544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Watkins W. M., Chulay J. D., Sixsmith D. G., Spencer H. C., Howells R. E. A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. J Pharm Pharmacol. 1987 Apr;39(4):261–265. doi: 10.1111/j.2042-7158.1987.tb06263.x. [DOI] [PubMed] [Google Scholar]
  23. Weidekamm E., Plozza-Nottebrock H., Forgo I., Dubach U. C. Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. Bull World Health Organ. 1982;60(1):115–122. [PMC free article] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES